Jade Biosciences, Inc. Income Statement
JBIO / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $21.4M | $17.2M | $14.6M | $8.0M | $949.0K |
| R&D Expense | $53.2M | $64.2M | $38.6M | $15.0M | $7.9M |
| Operating Income | -$74.6M | -$81.4M | -$53.2M | -$23.0M | -$8.9M |
| Interest Expense | - | - | - | - | $75.0K |
| Income Tax | $55.0K | $56.0K | $25.0K | $3.0K | - |
| Net Income | -$69.6M | -$75.5M | -$51.5M | -$23.0M | -$9.6M |
| EPS (Basic) | -$2.44 | -$2.87 | -$2.10 | -$1.87 | - |
| EPS (Diluted) | -$2.44 | -$2.87 | -$2.10 | -$1.87 | - |
| Shares Outstanding | 28.6M | 26.3M | 24.5M | 12.3M | 242.2K |